<?xml version='1.0' encoding='utf-8'?>
<document id="31527544"><sentence text="Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators."><entity charOffset="51-61" id="DDI-PubMed.31527544.s1.e0" text="Loxoprofen" /></sentence><sentence text="Loxoprofen (LOX) is a non-selective cyclooxygenase inhibitor that is widely used for the treatment of pain and inflammation caused by chronic and transitory conditions"><entity charOffset="0-10" id="DDI-PubMed.31527544.s2.e0" text="Loxoprofen" /><entity charOffset="12-15" id="DDI-PubMed.31527544.s2.e1" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s2.e0" e2="DDI-PubMed.31527544.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s2.e0" e2="DDI-PubMed.31527544.s2.e1" /></sentence><sentence text=" Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive"><entity charOffset="41-49" id="DDI-PubMed.31527544.s3.e0" text="carbonyl" /><entity charOffset="85-94" id="DDI-PubMed.31527544.s3.e1" text="trans-LOX" /><entity charOffset="91-99" id="DDI-PubMed.31527544.s3.e2" text="LOX" /><entity charOffset="121-129" id="DDI-PubMed.31527544.s3.e3" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e0" e2="DDI-PubMed.31527544.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e0" e2="DDI-PubMed.31527544.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e0" e2="DDI-PubMed.31527544.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e0" e2="DDI-PubMed.31527544.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e1" e2="DDI-PubMed.31527544.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e1" e2="DDI-PubMed.31527544.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e1" e2="DDI-PubMed.31527544.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e2" e2="DDI-PubMed.31527544.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s3.e2" e2="DDI-PubMed.31527544.s3.e3" /></sentence><sentence text=" In addition, LOX can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP)"><entity charOffset="14-16" id="DDI-PubMed.31527544.s4.e0" text="LOX" /><entity charOffset="85-87" id="DDI-PubMed.31527544.s4.e1" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s4.e0" e2="DDI-PubMed.31527544.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s4.e0" e2="DDI-PubMed.31527544.s4.e1" /></sentence><sentence text=" In a previous study, we reported that CYP3A4 is primarily responsible for the formation of OH-LOX in human liver microsomes"><entity charOffset="95-97" id="DDI-PubMed.31527544.s5.e0" text="LOX" /></sentence><sentence text=" Although metabolism by CYP3A4 does not produce active metabolites, it can affect the conversion of LOX into trans-/cis-LOX, since CYP3A4 activity modulates the substrate LOX concentration"><entity charOffset="100-102" id="DDI-PubMed.31527544.s6.e0" text="LOX" /><entity charOffset="120-122" id="DDI-PubMed.31527544.s6.e1" text="LOX" /><entity charOffset="171-173" id="DDI-PubMed.31527544.s6.e2" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s6.e0" e2="DDI-PubMed.31527544.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s6.e0" e2="DDI-PubMed.31527544.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s6.e0" e2="DDI-PubMed.31527544.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s6.e1" e2="DDI-PubMed.31527544.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s6.e1" e2="DDI-PubMed.31527544.s6.e2" /></sentence><sentence text=" Although the pharmacokinetics (PK) and metabolism of LOX have been well defined, its CYP-related interactions have not been fully characterized"><entity charOffset="54-56" id="DDI-PubMed.31527544.s7.e0" text="LOX" /></sentence><sentence text=" Therefore, we investigated the metabolism of LOX after pretreatment with dexamethasone (DEX) and ketoconazole (KTC), which induce and inhibit the activities of CYP3A, respectively"><entity charOffset="74-87" id="DDI-PubMed.31527544.s8.e0" text="dexamethasone" /><entity charOffset="89-92" id="DDI-PubMed.31527544.s8.e1" text="DEX" /><entity charOffset="98-110" id="DDI-PubMed.31527544.s8.e2" text="ketoconazole" /><entity charOffset="112-115" id="DDI-PubMed.31527544.s8.e3" text="KTC" /><entity charOffset="46-48" id="DDI-PubMed.31527544.s8.e4" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e4" e2="DDI-PubMed.31527544.s8.e4" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e4" e2="DDI-PubMed.31527544.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e4" e2="DDI-PubMed.31527544.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e4" e2="DDI-PubMed.31527544.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e4" e2="DDI-PubMed.31527544.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e0" e2="DDI-PubMed.31527544.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e0" e2="DDI-PubMed.31527544.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e0" e2="DDI-PubMed.31527544.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e0" e2="DDI-PubMed.31527544.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e1" e2="DDI-PubMed.31527544.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e1" e2="DDI-PubMed.31527544.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e1" e2="DDI-PubMed.31527544.s8.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e2" e2="DDI-PubMed.31527544.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s8.e2" e2="DDI-PubMed.31527544.s8.e3" /></sentence><sentence text=" We monitored their effects on the PK parameters of LOX, cis-LOX, and trans-LOX in mice, and demonstrated that their PK parameters significantly changed in the presence of DEX or KTC pretreatment"><entity charOffset="52-54" id="DDI-PubMed.31527544.s9.e0" text="LOX" /><entity charOffset="61-63" id="DDI-PubMed.31527544.s9.e1" text="LOX" /><entity charOffset="76-78" id="DDI-PubMed.31527544.s9.e2" text="LOX" /><entity charOffset="172-174" id="DDI-PubMed.31527544.s9.e3" text="DEX" /><entity charOffset="179-181" id="DDI-PubMed.31527544.s9.e4" text="KTC" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e0" e2="DDI-PubMed.31527544.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e0" e2="DDI-PubMed.31527544.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e0" e2="DDI-PubMed.31527544.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e0" e2="DDI-PubMed.31527544.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e0" e2="DDI-PubMed.31527544.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e1" e2="DDI-PubMed.31527544.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e1" e2="DDI-PubMed.31527544.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e1" e2="DDI-PubMed.31527544.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e1" e2="DDI-PubMed.31527544.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e2" e2="DDI-PubMed.31527544.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e2" e2="DDI-PubMed.31527544.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e2" e2="DDI-PubMed.31527544.s9.e4" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e3" e2="DDI-PubMed.31527544.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s9.e3" e2="DDI-PubMed.31527544.s9.e4" /></sentence><sentence text=" Specifically, DEX significantly decreased the concentration of the LOX active metabolite formed by CR, which corresponded to an increased concentration of OH-LOX formed by CYP3A4"><entity charOffset="156-162" id="DDI-PubMed.31527544.s10.e0" text="OH-LOX" /><entity charOffset="68-73" id="DDI-PubMed.31527544.s10.e1" text="LOX" /><entity charOffset="159-164" id="DDI-PubMed.31527544.s10.e2" text="LOX" /><entity charOffset="15-20" id="DDI-PubMed.31527544.s10.e3" text="DEX" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e3" e2="DDI-PubMed.31527544.s10.e3" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e3" e2="DDI-PubMed.31527544.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e3" e2="DDI-PubMed.31527544.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e3" e2="DDI-PubMed.31527544.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e1" e2="DDI-PubMed.31527544.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e1" e2="DDI-PubMed.31527544.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e1" e2="DDI-PubMed.31527544.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e0" e2="DDI-PubMed.31527544.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s10.e0" e2="DDI-PubMed.31527544.s10.e2" /></sentence><sentence text=" The opposite result occurred with KTC (a CYP3A inhibitor) pretreatment"><entity charOffset="35-37" id="DDI-PubMed.31527544.s11.e0" text="KTC" /></sentence><sentence text=" Thus, we conclude that concomitant use of LOX with CYP3A modulators may lead to drug-drug interactions and result in minor to severe toxicity even though there is no direct change in the metabolic pathway that forms the LOX active metabolite"><entity charOffset="43-45" id="DDI-PubMed.31527544.s12.e0" text="LOX" /><entity charOffset="221-223" id="DDI-PubMed.31527544.s12.e1" text="LOX" /><pair ddi="false" e1="DDI-PubMed.31527544.s12.e0" e2="DDI-PubMed.31527544.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31527544.s12.e0" e2="DDI-PubMed.31527544.s12.e1" /></sentence><sentence text="" /></document>